CA1189853A - Steroid compound and pharmaceutical compositions containing it - Google Patents

Steroid compound and pharmaceutical compositions containing it

Info

Publication number
CA1189853A
CA1189853A CA000413616A CA413616A CA1189853A CA 1189853 A CA1189853 A CA 1189853A CA 000413616 A CA000413616 A CA 000413616A CA 413616 A CA413616 A CA 413616A CA 1189853 A CA1189853 A CA 1189853A
Authority
CA
Canada
Prior art keywords
water
micronised
monohydrate
dipropionate
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000413616A
Other languages
English (en)
French (fr)
Inventor
John H. Hunt
John M. Padfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of CA1189853A publication Critical patent/CA1189853A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CA000413616A 1981-10-19 1982-10-18 Steroid compound and pharmaceutical compositions containing it Expired CA1189853A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8131425 1981-10-19
GB8131425 1981-10-19

Publications (1)

Publication Number Publication Date
CA1189853A true CA1189853A (en) 1985-07-02

Family

ID=10525238

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000413616A Expired CA1189853A (en) 1981-10-19 1982-10-18 Steroid compound and pharmaceutical compositions containing it

Country Status (22)

Country Link
US (1) US4866051A (enExample)
JP (1) JPS5890599A (enExample)
KR (1) KR890000664B1 (enExample)
AU (1) AU551471B2 (enExample)
BE (1) BE894725A (enExample)
CA (1) CA1189853A (enExample)
CH (1) CH652134A5 (enExample)
DE (1) DE3238569A1 (enExample)
DK (1) DK168389B1 (enExample)
DO (1) DOP1990004774A (enExample)
ES (1) ES516611A0 (enExample)
FI (1) FI73128C (enExample)
FR (1) FR2514769B1 (enExample)
HK (1) HK100989A (enExample)
IE (1) IE54170B1 (enExample)
IT (1) IT1196553B (enExample)
MY (1) MY8700910A (enExample)
NL (1) NL8204013A (enExample)
NZ (1) NZ202212A (enExample)
PT (1) PT75692A (enExample)
SE (1) SE454356B (enExample)
ZA (1) ZA827601B (enExample)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5766573A (en) * 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
US5208226A (en) * 1989-09-08 1993-05-04 Glaxo Group Limited Medicaments
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
SE9101090D0 (sv) * 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
NZ257212A (en) 1992-09-29 1996-11-26 Inhale Therapeutic Syst Parathyroid hormone formulations comprising a biologically active n-terminal fragment of the hormone
GB9322014D0 (en) * 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
KR100419037B1 (ko) 1994-03-07 2004-06-12 넥타르 테라퓨틱스 폐를통한인슐린의전달방법및그조성물
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
WO1997001341A1 (en) * 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. The combination of topical nasal mast cell stabilizers and topical nasal steroids
US5987746A (en) * 1996-02-21 1999-11-23 Medtronic, Inc. Method of making medical electrical lead
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
GB9826284D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ES2395096T3 (es) * 1999-06-29 2013-02-08 Mannkind Corporation Purificación y estabilización de agentes farmacéuticos a base de péptidos y proteínas
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
EP1311294A2 (en) * 2000-08-04 2003-05-21 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
WO2003037303A1 (en) * 2001-11-01 2003-05-08 Nektar Therapeutics Spray drying methods and compositions thereof
ES2364636T3 (es) 2001-12-19 2011-09-08 Novartis Ag Administración pulmonar de aminoglucósidos.
SI1494732T1 (sl) 2002-03-20 2008-08-31 Mannking Corp Inhalacijski aparat
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
JP4532281B2 (ja) * 2002-11-08 2010-08-25 株式会社カネカ エルゴステロールの分離方法
US7338171B2 (en) * 2003-10-27 2008-03-04 Jen-Chuen Hsieh Method and apparatus for visual drive control
US20050153874A1 (en) * 2004-01-12 2005-07-14 Mannkind Corporation Method of reducing serum proinsulin levels in type 2 diabetics
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080248999A1 (en) * 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
KR101273120B1 (ko) 2004-08-20 2013-06-13 맨카인드 코포레이션 다이케토피페라진 합성의 촉매 작용
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
US20060204601A1 (en) * 2005-03-09 2006-09-14 Palu Afa K Formulations and methods for preventing and treating substance abuse and addiction
CN101312713A (zh) * 2005-03-18 2008-11-26 纳米材料科技有限公司 可吸入的药物
KR101486829B1 (ko) 2005-09-14 2015-01-29 맨카인드 코포레이션 결정질 미립자 표면에 대한 활성제의 친화력의 증가를 기반으로 하는 약물 제제의 방법
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20070086952A1 (en) * 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
JP2009533471A (ja) * 2006-04-12 2009-09-17 バイオデル， インコーポレイテッド 即効型および長時間作用型組合せインスリン製剤
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
DK2425820T3 (en) 2007-02-11 2015-07-13 Map Pharmaceuticals Inc A method for the therapeutic administration of DHE in order to enable quick relief of migraine, while minimizing the adverse event profile
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
AU2009204309B2 (en) * 2008-01-04 2012-11-22 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
GB0806873D0 (en) * 2008-04-16 2008-05-21 Breath Ltd Steroid nebuliser formulation
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
TWI677355B (zh) 2008-06-13 2019-11-21 美商曼凱公司 用於藥物傳輸之乾粉吸入器及系統
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
EP2676695A3 (en) 2009-03-11 2017-03-01 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
MY186975A (en) 2009-06-12 2021-08-26 Mannkind Corp Diketopiperazine microparticles with defined specific surface areas
GB0914231D0 (en) * 2009-08-14 2009-09-30 Breath Ltd Dry powder inhaler formulations
US9016147B2 (en) 2009-11-03 2015-04-28 Mannkind Corporation Apparatus and method for simulating inhalation efforts
MX359281B (es) 2010-06-21 2018-09-21 Mannkind Corp Sistema y metodos para suministrar un farmaco en polvo seco.
US8925726B2 (en) 2011-04-01 2015-01-06 Mannkind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CA2852536A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
CA2878457C (en) 2012-07-12 2021-01-19 Mannkind Corporation Dry powder drug delivery systems and methods
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
EP2970149B1 (en) 2013-03-15 2019-08-21 MannKind Corporation Microcrystalline diketopiperazine compositions and methods
EP3021834A1 (en) 2013-07-18 2016-05-25 MannKind Corporation Heat-stable dry powder pharmaceutical compositions and methods
CN105517607A (zh) 2013-08-05 2016-04-20 曼金德公司 吹入设备和方法
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
CA3103679A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition
IT201800007527A1 (it) * 2018-07-26 2020-01-26 Sofar Spa Composizione contenente beclometasone per la prevenzione e il trattamento di prostatiti batteriche e vaginiti

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1047519A (en) * 1963-06-11 1966-11-02 Glaxo Lab Ltd 17ª‡,21-diesters of 11,17,21-trihydroxy steroid compounds
GB1429184A (en) * 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
NZ177056A (en) * 1974-03-27 1978-09-20 Plurichemie Anstalt Certain 9 -(chloro or flruoro)-16( or )-methyl-11 ,17 -dihydroxypregna-1,4-diene-3,20-dione 17 -acylates or 11 ,17 -diacylates and certain preparature processes
GB1571629A (en) * 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate
IT1121513B (it) * 1979-05-28 1986-04-02 Chiesi Farma Spa Processo per la conversione di umo steroide antiinfiammatorio in una forma suscettibile di essere somministarta come aerosol
ATE3774T1 (de) * 1980-05-02 1983-06-15 Schering Corporation Beclomethason-ester-solvate, verfahren zu ihrer herstellung und herstellung einer formulierung.
FI63672C (fi) * 1980-05-19 1983-08-10 Orion Yhtymae Oy Foerfarande foer framstaellning av en blandning av beklometasondipropionat och triklorfluormetan eller diklordifluormetan
PT71309A (en) * 1980-05-27 1980-06-01 Hovione Sociedade Quimica Lda Process of selective
CH649923A5 (de) * 1980-10-06 1985-06-28 Glaxo Group Ltd Topisch verabreichbare pharmazeutische zusammensetzungen, enthaltend anti-inflammatorische steroide.
US4391755A (en) * 1982-01-18 1983-07-05 E. R. Squibb & Sons, Inc. Steroid monohydrates, formulations containing same and method
IE59086B1 (en) * 1984-07-25 1994-01-12 Hovione Int Ltd Preparation and use of new solvates of beclomthasone 17,21-dipropionate
GB8432063D0 (en) * 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids

Also Published As

Publication number Publication date
SE8205904L (sv) 1983-04-20
ZA827601B (en) 1983-09-28
IE54170B1 (en) 1989-07-05
FI823561A0 (fi) 1982-10-18
AU551471B2 (en) 1986-05-01
IE822514L (en) 1983-04-19
FR2514769B1 (fr) 1985-08-30
KR840002007A (ko) 1984-06-11
AU8946082A (en) 1984-05-03
MY8700910A (en) 1987-12-31
SE8205904D0 (sv) 1982-10-18
FI73128C (fi) 1987-09-10
DE3238569C2 (enExample) 1991-01-31
PT75692A (en) 1982-11-01
IT8249294A0 (it) 1982-10-18
NL8204013A (nl) 1983-05-16
IT8249294A1 (it) 1984-04-18
SE454356B (sv) 1988-04-25
FI823561L (fi) 1983-04-20
FR2514769A1 (fr) 1983-04-22
DOP1990004774A (es) 1996-02-02
DE3238569A1 (de) 1983-05-05
HK100989A (en) 1989-12-29
KR890000664B1 (ko) 1989-03-22
JPS5890599A (ja) 1983-05-30
DK461182A (da) 1983-04-20
IT1196553B (it) 1988-11-16
BE894725A (fr) 1983-04-18
DK168389B1 (da) 1994-03-21
NZ202212A (en) 1986-01-24
CH652134A5 (de) 1985-10-31
ES8404374A1 (es) 1984-05-01
ES516611A0 (es) 1984-05-01
FI73128B (fi) 1987-05-29
US4866051A (en) 1989-09-12
JPH0424358B2 (enExample) 1992-04-24

Similar Documents

Publication Publication Date Title
CA1189853A (en) Steroid compound and pharmaceutical compositions containing it
US4364923A (en) Chemical compounds
US6030604A (en) Formulation for inhalation
US7354913B2 (en) High storage stability inhalable compositions
EP1005328B1 (en) Composition comprising finely divided, crystalline particles of budesonide
US7179489B2 (en) Process for preparing a pharmaceutical composition containing an active ingredient and a micronised carrier/diluent
EP0039369A1 (en) Beclomethasone ester solvates, process for their preparation, and preparation of a formulation
GB2107715A (en) Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
EP1572153B1 (en) Preparation of sterile aqueous suspensions comprising micronised crystalline active ingredients for inhalation
AU2001259007A1 (en) Novel composition
CA1075228A (en) Flunisolide to treat respiratory diseases
EP1542753B1 (en) Pharmaceutical compositions
CN108473437B (zh) 7-氮杂双环[2.2.1]庚烷衍生物的干粉吸入器组合物
CN1353980A (zh) 速效平喘气雾剂及其制备方法
EP1785156B1 (en) Metered dose inhaler containing an aerosol suspension formulation
HK1103999A (en) Pharmaceutical compositions
HK1124782A (en) Composition comprising formoterol and a glucocorticosteroid
HU180348B (hu) Eljárás beklometazon-észter-szolvátok előállítására
HK1025515B (en) New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof

Legal Events

Date Code Title Description
MKEC Expiry (correction)
MKEX Expiry